Want to see NIKI full AI Analyst Report?
NIKI Stock Chart & Stats
$8.38
-$0.20(-2.33%)
At close: 4:00 PM EDT
$8.38
-$0.20(-2.33%)
Day’s Range― - ―
52-Week Range$6.00 - $44.70
Previous CloseN/A
Volume50.61K
Average Volume (3M)113.32K
Market Cap
$6.82M
Enterprise Value-$2.15
Total Cash (Recent Filing)$3.45M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding634,682
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31
Revenue Forecast (FY)$106.80M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetModerate leverage, improving debt-to-equity and a sizable equity cushion give the company a tangible buffer. For a clinical-stage biotech this reduces immediate solvency pressure, preserving runway and optionality to fund trials or negotiate partnerships over the next several months.
Clear Asset-advancement Business ModelA focused strategy of advancing candidates and monetizing via licensing or partnerships matches industry norms for clinical-stage biotechs. This model provides multiple durable paths to value realization (milestones, royalties, collaborations) that can materialize without immediate product sales.
Improving Cash Burn And Narrowed LossesReduced operating outflows and a meaningful narrowing of net loss in 2025 versus 2024 indicates progress in cost control or program prioritization. This improvement lengthens runway, lowers near-term financing needs and supports executing development milestones over the next 2–6 months.
Bears Say
Minimal Revenue / No Commercial ScaleAn absence of material operating revenue removes self-funding capability and increases dependence on external financing or partnerships. Over a multi-month horizon this constrains flexibility, raises dilution risk, and heightens the company's reliance on execution of development or licensing events to generate cash.
Persistent Negative Operating Cash FlowSustained negative cash generation depletes resources and forces repeated financing or asset monetization. Even with recent improvement, ongoing outflows mean near-term programs and milestones depend on external capital, which can limit strategic choices and increase dilution or financing costs.
Ongoing Net Losses And Negative ReturnsConsistently negative profitability and ROE signal persistent value erosion and weak operating leverage. This undermines long-term investor confidence, can weaken negotiating power for collaborations, and implies the company must show clear clinical or licensing progress to reverse structural underperformance.
NIKI FAQ
What was Niki BioSolutions Inc’s price range in the past 12 months?
Niki BioSolutions Inc lowest stock price was $6.00 and its highest was $44.70 in the past 12 months.
What is Niki BioSolutions Inc’s market cap?
Niki BioSolutions Inc’s market cap is $6.82M.
When is Niki BioSolutions Inc’s upcoming earnings report date?
Niki BioSolutions Inc’s upcoming earnings report date is Sep 15, 2026 which is in 48 days.
How were Niki BioSolutions Inc’s earnings last quarter?
Currently, no data Available
Is Niki BioSolutions Inc overvalued?
According to Wall Street analysts Niki BioSolutions Inc’s price is currently Overvalued.
Does Niki BioSolutions Inc pay dividends?
Niki BioSolutions Inc does not currently pay dividends.
What is Niki BioSolutions Inc’s EPS estimate?
Niki BioSolutions Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Niki BioSolutions Inc have?
Niki BioSolutions Inc has 634,682 shares outstanding.
What happened to Niki BioSolutions Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Niki BioSolutions Inc?
Currently, no hedge funds are holding shares in NIKI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Niki BioSolutions Inc
Aptorum Group Limited (APM) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for diseases with significant unmet medical need. The company’s activities center on drug discovery and development, including preclinical and clinical advancement of product candidates, with an emphasis on areas such as infectious diseases and oncology. Aptorum also engages in strategies intended to accelerate development, which may include in-licensing, out-licensing, and collaborations related to its pipeline assets.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors